Ned Pagliarulo

BioTech

Namandjé Bumpus, FDA’s No. 2 official, to depart agency at end of year

Listen to the article 2 min This audio is auto-generated. Please let us know if you have feedback. Namandjé Bumpus, the Food and Drug Administration’s

Ned Pagliarulo December 18, 2024

BioTech

J&J to phase out Janssen name in corporate rebrand

Janssen, a brand name that for six decades has been emblazoned on Johnson & Johnson’s pharmaceutical laboratories and prescription drugs, will be phased out as

Ned Pagliarulo September 15, 2023

BioTech

Bausch + Lomb bulks up OTC business with J&J deal

Dive Brief: Bausch + Lomb continues to bulk up via dealmaking, announcing Thursday a deal to buy a line of eye and contact lens drops

Ned Pagliarulo July 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Ned Pagliarulo

Namandjé Bumpus, FDA’s No. 2 official, to depart agency at end of year

J&J to phase out Janssen name in corporate rebrand

Bausch + Lomb bulks up OTC business with J&J deal

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe